NCT06455358View on ClinicalTrials.gov

61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Neuroendocrine Tumors
Interventions
DRUG

61Cu-NODAGA-LM3

Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.

OTHER

Comparator

Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Department of Radiology and Nuclear Medicine, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER